NCT00070993View on ClinicalTrials.gov

Creatine for the Treatment of Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

December 31, 2002

Study Completion Date

May 31, 2006

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

creatine monohydrate

Trial Locations (6)

22908

University of Virginia Health System, Charlottesville

60612

Rush-Presbyterian St. Luke's Medical Center, Chicago

66160

University of Kansas Medical Center, Kansas City

78284

University of Texas Health and Science Center, San Antonio

87131

University of New Mexico - Medical Center, Albuquerque

94115

California Pacific Medical Center, San Francisco

All Listed Sponsors
collaborator

Office of Dietary Supplements (ODS)

NIH

lead

National Center for Complementary and Integrative Health (NCCIH)

NIH

NCT00070993 - Creatine for the Treatment of Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter